Evidence map›Paper›PMID 37448561›Full record

ArticleiScience2023

Microsatellite instability states serve as predictive biomarkers for tumors chemotherapy sensitivity.

Taojun Ye, Anqi Lin, Zhengang Qiu, Shulu Hu, Chaozheng Zhou, Zaoqu Liu, Quan Cheng, Jian Zhang, Peng Luo

Open access · goldAbstract read
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Taojun YeDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Anqi LinDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Zhengang QiuThe First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Shulu HuDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Chaozheng ZhouDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Zaoqu LiuThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Quan ChengXiangya Hospital, Central South University, Changsha, Hunan, China.
Jian ZhangDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Peng LuoDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Zhujiang Hospital · CNCentral South University · CNFirst Affiliated Hospital of Gannan Medical University · CNFirst Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an urgent need for markers to predict the efficacy of different chemotherapy drugs. Herein, we examined whether microsatellite instability (MSI) status can predict tumor multidrug sensitivity and explored the underlying mechanisms. We downloaded data from several public databases. Drug sensitivity was compared between the high microsatellite instability (MSI-H) and microsatellite-stable/low microsatellite instability (MSS/MSI-L) groups. In addition, we performed pathway enrichment analysis and cellular chemosensitivity assays to explore the mechanisms by which MSI status may affect drug sensitivity and assessed the differences between drug-treated and control cell lines. We found that multiple MSI-H tumors were more sensitive to a variety of chemotherapy drugs than MSS/MSI-L tumors, and especially for CRC, chemosensitivity is enhanced through the downregulation of DDR pathways such as NHEJ. Additional DNA damage caused by chemotherapeutic drugs results in further downregulation of DDR pathways and enhances drug sensitivity, forming a cycle of increasing drug sensitivity.

Indexed as

Cell biologyMolecular biology

Identifiers

PMID37448561
PMCPMC10336167
OpenAlexW4379742488

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.